Accelerate Time-To-Market With a Proven Team of GI Experts

Tap into our extensive network of 5,000+ sites, leveraging exclusive data from central imaging projects in endoscopy and histopathology, and benefit from our team of medical and operational GI experts for swift study startup and accelerated patient recruitment.
In more than 60 countries
Supporting >70% of IBD compounds currently in development
Unrivaled KOL network

Therapeutic Focus

Alimentiv stands at the forefront of patient recruitment and imaging innovations for gastrointestinal and liver diseases, driving health breakthroughs through advanced research, accelerated clinical trials, and delivering actionable biomarker insights. We are dedicated to redefining the future of GI and liver clinical research.

Services

With over 30 years of pioneering advancements in gastrointestinal therapeutics, Alimentiv continues to advance clinical trials through medical research, development, and imaging solutions. Our team offers streamlined solutions for all stages of clinical development, from early phase 1 to phase 4 trials.


Latest Updates

Article Dec 20, 2024
Advancing EoE Histopathology With Emerging AI Solutions From Alimentiv

Disclaimer*The AI-based algorithm for automated PEC developed by Alimentiv is not a medical device and is not used by healthcare professionals for clinical diagnosis or...

Publication Dec 4, 2024
Meta-Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials

Anila Qasim, Brian Feagan, Christopher Ma, David B O'Gorman, Vipul Jairath

News Nov 18, 2024
Alimentiv Partners on a New Alcoholic Hepatitis Phase 1b Clinical Trial

September 2024 – Alimentiv is proud to partner on an exciting new Phase 1b clinical trial in severe alcohol-associated hepatitis, an area with high mortality...

Speak to a member
of our expert team

Contact us